Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies.

Bruce H ChamberlainMichelle RhinerNeal E SlatkinNancy StamblerRobert J Israel

Published in: Journal of pain research (2021)

Methylnaltrexone reduced RFL time in advanced-illness patients with and without active cancer, while maintaining pain control with opioid treatment despite higher baseline opioid use among cancer patients.

Keyphrases

chronic pain
pain management
papillary thyroid
end stage renal disease
newly diagnosed
ejection fraction
squamous cell
chronic kidney disease
prognostic factors
neuropathic pain
combination therapy
peritoneal dialysis
childhood cancer
case control